CareDx Inc (CDNA) Q3 2024 Earnings Call Highlights: Robust Revenue Growth and Strategic ...

GuruFocus.com11-05

Revenue: $82.9 million, representing 23% year-over-year growth. Gross Margin: 69%, up 240 basis points from the previous year. Adjusted EBITDA: $6.9 million, compared to a $10.9 million loss in the ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2481547542?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/p5qqwvXgygGn79qh2T5KQQ--~B/aD0zNTE7dz0zNTE7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/44ff9e9f6d65332e2636bcc37d46abf4","is_english":true,"pubTime":"2024-11-05 15:06","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2481547542","market":"us","top_or_hot":-1,"title":"CareDx Inc (CDNA) Q3 2024 Earnings Call Highlights: Robust Revenue Growth and Strategic ...","media":"GuruFocus.com","content":"<div>\n<p>Revenue: $82.9 million, representing 23% year-over-year growth.\nGross Margin: 69%, up 240 basis points from the previous year.\nAdjusted EBITDA: $6.9 million, compared to a $10.9 million loss in the ...</p>\n\n<a href=\"https://finance.yahoo.com/news/caredx-inc-cdna-q3-2024-070656996.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CareDx Inc (CDNA) Q3 2024 Earnings Call Highlights: Robust Revenue Growth and Strategic ...</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCareDx Inc (CDNA) Q3 2024 Earnings Call Highlights: Robust Revenue Growth and Strategic ...\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-05 15:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/caredx-inc-cdna-q3-2024-070656996.html><strong>GuruFocus.com</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Revenue: $82.9 million, representing 23% year-over-year growth.\nGross Margin: 69%, up 240 basis points from the previous year.\nAdjusted EBITDA: $6.9 million, compared to a $10.9 million loss in the ...</p>\n\n<a href=\"https://finance.yahoo.com/news/caredx-inc-cdna-q3-2024-070656996.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CDNA","symbol_name":"CareDx","start_time":0,"source_url":"https://finance.yahoo.com/news/caredx-inc-cdna-q3-2024-070656996.html","article_id":"2481547542","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/p5qqwvXgygGn79qh2T5KQQ--~B/aD0zNTE7dz0zNTE7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/44ff9e9f6d65332e2636bcc37d46abf4"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481547542","pubTimestamp":1730790416,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Gross Margin: 69%, up 240 basis points from the previous year.Adjusted EBITDA: $6.9 million, compared to a $10.9 million loss in the same quarter last year.Cash and Cash Equivalents: $241 million, with no debt.Testing Services Revenue: $60.8 million, up 27% year-over-year.Testing Services Volume: Approximately 44,600 tests, up 16% year-over-year.Patient and Digital Solutions Revenue: $11.9 million, up 20% year-over-year.Revised 2024 Revenue Guidance: Increased to $327 million to $331 million.GuruFocus has detected 6 Warning Signs with CDNA.For the complete transcript of the earnings call, please refer to the full earnings call transcript.CareDx Inc  reported a strong quarter with a 23% year-over-year revenue growth, reaching $82.9 million.Despite strong growth, the guidance for 2025 indicates a slowdown to low teens revenue growth, raising concerns about sustaining current growth rates.A: Abhishek Jain noted that the 17% year-over-year growth includes a one-time $14 million revenue. Ex","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"CDNA":"CareDx"},"translate_title":"CareDx Inc(CDNA)2024年第三季度收益看涨期权亮点：强劲的收入增长和战略……","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CDNA":1},"content_text":"Revenue: $82.9 million, representing 23% year-over-year growth.\nGross Margin: 69%, up 240 basis points from the previous year.\nAdjusted EBITDA: $6.9 million, compared to a $10.9 million loss in the same quarter last year.\nCash from Operations: $12.5 million generated.\nCash and Cash Equivalents: $241 million, with no debt.\nTesting Services Revenue: $60.8 million, up 27% year-over-year.\nTesting Services Volume: Approximately 44,600 tests, up 16% year-over-year.\nPatient and Digital Solutions Revenue: $11.9 million, up 20% year-over-year.\nProducts Revenue: $10.2 million, up 7% year-over-year.\nRevised 2024 Revenue Guidance: Increased to $327 million to $331 million.\n\n\nWarning! GuruFocus has detected 6 Warning Signs with CDNA.\n\nRelease Date: November 04, 2024\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.\n Positive Points \n\nCareDx Inc (NASDAQ:CDNA) reported a strong quarter with a 23% year-over-year revenue growth, reaching $82.9 million.\nThe company achieved positive adjusted EBITDA of $6.9 million, surpassing their guidance of being EBITDA neutral.\nCareDx Inc (NASDAQ:CDNA) ended the quarter with a robust balance sheet, holding $241 million in cash and cash equivalents with no debt.\nTesting services saw a 16% increase in volume, marking the fifth consecutive quarter of sequential growth.\nThe company successfully expanded its gross margins and managed expenses efficiently, contributing to its positive financial performance.\n\n Negative Points \n\nThe company anticipates a 1% impact on testing volumes in Q4 due to Hurricane Milton, which has not yet been recovered.\nDespite strong growth, the guidance for 2025 indicates a slowdown to low teens revenue growth, raising concerns about sustaining current growth rates.\nProduct gross margins decreased to 46% from 58% in the same quarter last year, indicating variability in production schedules.\nThe company is facing ongoing legal challenges, including a jury verdict against its prior testing process, which remains under court review.\nThere is uncertainty regarding the timing of new draft LCDs from Medicare, which could impact future coverage and reimbursement.\n\n Q & A Highlights \nQ: Why does the Q4 guidance appear flat compared to Q3, despite expectations for Q4 to be stronger? A: Abhishek Jain, Chief Financial Officer, explained that the Q4 guidance is in line with Q3 due to prior period revenue adjustments. Excluding these, Q4 shows growth. Testing services are expected to see volume growth similar to past trends.\nQ: How should we interpret the projected low teens revenue growth for next year, given the strong growth reported this quarter? A: Abhishek Jain noted that the 17% year-over-year growth includes a one-time $14 million revenue. Excluding this, the growth aligns with the projected low teens for 2025. Investments in the commercial team and billing operations are expected to drive higher growth in subsequent years.\nQ: Can you provide more details on the surveillance testing mix and its potential growth? A: John Hanna, President and CEO, mentioned that while specific mix rates weren't disclosed, there has been a modest shift towards surveillance testing. It is expected to take 2 to 3 quarters for full adoption of surveillance protocols by transplant centers.\nQ: With over $230 million in cash, how is CareDx planning to allocate capital if acquisitions aren't pursued? A: John Hanna stated that the focus is on growth and profitable expansion. Investments will be made into the core business to drive growth before considering share buybacks.\nQ: What are the expectations for transplant procedures in 2025, and what factors might influence this trend? A: John Hanna indicated that the baseline expectation is mid-single-digit growth in the transplant market. Factors like government programs could influence this, but no immediate catalysts are identified.\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.This article first appeared on \nGuruFocus.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2481547542"}